Why the study?
What are the strategies and outcomes of repeat interventions after failed MitraClip therapy in patients with severe mitral regurgitation?
What are the strategies and outcomes of repeat interventions after failed MitraClip therapy in patients with severe mitral regurgitation?
This review provides a summary of strategies and outcomes for managing patients who require repeat interventions after failed MitraClip therapy.
Summarizes reintervention options after failed MitraClip; leaves open optimal strategies pending prospective data.
Percutaneous mitral valve repair (PMVR) with the MitraClip system (Abbott Vascular, Santa Clara, CA, USA) is a valid therapeutic option for patients with severe mitral regurgitation (MR) deemed to be at high or prohibitive surgical risk. Despite the reassuring data on efficacy and long-term durability of the procedure, the proportion of patients with residual or relapsing severe MR after MitraClip therapy is not negligible. In light of the detrimental prognostic impact of severe MR, repeat interventions are increasingly performed in clinical practice using different techniques. In high-risk settings, percutaneous procedures have proven to be effective and safe at reducing MR. Building on this, we sought to summarize the current landscape and clinical experience of reinterventions after failed MitraClip therapy, so as to assist physicians facing the clinical hurdle of proper treatment management after failed PMVR.
No takes yet. Share an insight, caveat, or question.
Grasso et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: